[go: up one dir, main page]

MX9709189A - Metodos para inhibir la migracion de celulas de musculo liso vascular. - Google Patents

Metodos para inhibir la migracion de celulas de musculo liso vascular.

Info

Publication number
MX9709189A
MX9709189A MX9709189A MX9709189A MX9709189A MX 9709189 A MX9709189 A MX 9709189A MX 9709189 A MX9709189 A MX 9709189A MX 9709189 A MX9709189 A MX 9709189A MX 9709189 A MX9709189 A MX 9709189A
Authority
MX
Mexico
Prior art keywords
methods
smooth muscle
cell migration
muscle cell
vascular smooth
Prior art date
Application number
MX9709189A
Other languages
English (en)
Other versions
MXPA97009189A (es
Inventor
Jai Pal Singh
Todd Robert Wiernicki
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9709189A publication Critical patent/MX9709189A/es
Publication of MXPA97009189A publication Critical patent/MXPA97009189A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan métodos para inhibir la migracion de células de musculos liso vascular, que comprende administrar a un humano u otro mamífero en necesidad de tratamiento una cantidad efectiva de un compuesto que tiene la formula (I) en la que R1 y R2 son independientemente hidrogeno -CH3, (a) o (b), en donde Ar es fenilo opcionalmente sustituido; R2 es pirrolidino, hexametilenimino o piperidino; y sales y solvatos del mismo farmacéuticamente aceptables.
MXPA/A/1997/009189A 1995-06-01 1997-11-27 Metodos para inhibir la migracion de celulas de musculo liso vascular MXPA97009189A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08457700 1995-06-01
US08/457,700 US5622975A (en) 1995-06-01 1995-06-01 Methods for inhibiting vascular smooth muscle cell migration
PCT/US1996/008037 WO1996038145A1 (en) 1995-06-01 1996-05-30 Methods for inhibiting vascular smooth muscle cell migration

Publications (2)

Publication Number Publication Date
MX9709189A true MX9709189A (es) 1998-03-31
MXPA97009189A MXPA97009189A (es) 1998-10-15

Family

ID=

Also Published As

Publication number Publication date
AU5954196A (en) 1996-12-18
IL118483A0 (en) 1996-09-12
CA2222292A1 (en) 1996-12-05
RO117996B1 (ro) 2002-12-30
MY112973A (en) 2001-10-31
CN1191487A (zh) 1998-08-26
ZA964439B (en) 1997-12-01
EP0745384A2 (en) 1996-12-04
NO975369D0 (no) 1997-11-21
HUP9900851A2 (hu) 1999-09-28
KR19990022053A (ko) 1999-03-25
EA199700450A1 (ru) 1998-06-25
US5622975A (en) 1997-04-22
HUP9900851A3 (en) 1999-11-29
NZ309390A (en) 2000-07-28
CZ287958B6 (cs) 2001-03-14
EA000190B1 (ru) 1998-12-24
CZ374497A3 (cs) 1998-06-17
CN1089237C (zh) 2002-08-21
AU707756B2 (en) 1999-07-22
IL118483A (en) 2000-06-29
WO1996038145A1 (en) 1996-12-05
EP0745384A3 (en) 1997-02-26
NO975369L (no) 1997-11-21
PL323786A1 (en) 1998-04-27
UA42835C2 (uk) 2001-11-15
YU32196A (sh) 1999-06-15
JPH11509836A (ja) 1999-08-31

Similar Documents

Publication Publication Date Title
MY112973A (en) Methods for inhibiting vascular smooth muscle cell migration
IL111288A (en) Uses of 2-phenyl-3-aroylbenzothiophenes and 3-phenyl-4-aroyl-1,2-dihydronaphthalenes for the preparation of a medicament for inhibiting smooth muscle cell proliferation and restinosis
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
SG46324A1 (en) Methods of inhibiting uterine fibrosis
SI0652002T1 (en) Use of 2-phenyl-3-aroylbenzothiophenes for the preparation of a medicament for inhibiting cartilage degradation
AU7578694A (en) Methods for treating resistant neoplasms
UA27910C2 (uk) Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с
MX9701334A (es) Metodos para inhibir la degeneracion de protesis oseas.
MX9709466A (es) Medicamento para inhibir el melanoma.
MX9701333A (es) Metodos para inhibir el daño neuronal.
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.
MX9701359A (es) Metodos para la inhibicion de la hiperplasia endometrial primaria.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9705697A (es) Metodos para reducir los niveles de calcio del suero.
MX9702853A (es) Metodos para inhibir condiciones asociadas con el neuropeptido "y".
MX9706072A (es) Metodos de inhibicion de la adhesion celula-celula.
MX9709651A (es) Metodos para modulacion del factor de transcripcion nf-kb.
MX9705537A (es) Metodos y composiciones para inhibir el efecto de los estrogenos del medio ambiente.